Pulmonary Metabolism of Resveratrol: In Vitro and In Vivo Evidence

Satish Sharan and Swati Nagar

Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania

Received January 30, 2013; accepted March 8, 2013

ABSTRACT

The role of pulmonary metabolism in trans-resveratrol (RES) pharmacokinetics was studied in a mouse model. Plasma concentrations of RES and its major metabolites trans-resveratrol-3-sulfate (R3S) and trans-resveratrol-3-glucuronide (R3G) were compared after administration of RES by intravenous (IV) and intra-arterial (IA) routes. Total area under the curve (AUC) of RES decreased by approximately 50% when RES was administered by the IV route compared with the IA route. The AUC of R3G was also significantly higher in mice administered RES by the IV route compared with the IA route. In vitro studies performed with mouse and human lung fractions confirmed pulmonary metabolism of RES. Interestingly, mouse-lung fractions gave rise to both R3S and R3G, whereas human lung fractions yielded R3S. This indicates marked interspecies variation in RES conjugation, especially in the context of extrapolating rodent data to humans. Taken together, the results presented here underline, for the first time, the impact of pulmonary metabolism on resveratrol pharmacokinetics and interspecies differences in RES pulmonary metabolism.

Introduction

The knowledge of extrahepatic metabolism in drug disposition is important. Extrahepatic drug metabolism can modify the systemic as well as tissue exposure of drug/metabolites, and this becomes especially important in cases of active metabolite formation and certain disease states. For example, in severe cirrhosis of the liver, extrahepatic metabolic pathways might compensate for the impaired hepatic elimination of a drug (Patwardhan et al., 1981). Tissue levels of drug/active metabolites might change, depending on the site of metabolism. For example, in the case of irinotecan, its active metabolite SN-38 (7-ethyl-10-hydroxy-camptothecin) is conjugated to SN-38 glucuronide in the liver, which is eliminated in the bile and metabolized by gut β-glucuronidase to regenerate SN-38. Locally formed SN-38 is thought to cause diarrhea (Araki et al., 1993; Takasuna et al., 1996; Michael et al., 2004). Thus, information about sites of metabolism is important for appropriately selecting a dosage regimen for various clinical conditions, as well as for selection of appropriate route of drug administration.

The route of drug administration can significantly change the disposition of parent drug and metabolites if extrahepatic eliminating organs are involved. Although a bioavailability of 100% is assumed on intravenous (IV) administration of a drug, pulmonary metabolism can decrease the bioavailability even on IV administration. Compounds administered orally must cross the gut and lungs in addition to the liver before reaching the arterial blood supply for distribution to tissues. The lung as a site of metabolism assumes significance as the entire cardiac output (approximately four times liver blood flow) perfuses the lung and can play an important role in drug disposition (Davies and Morris, 1993). It has been shown that phenolic compounds (e.g., harmol) (Mulder et al., 1984) and phenol (Cassidy and Houston, 1984) undergo pulmonary metabolism.

Trans-resveratrol (RES) is a dietary phytochemical known to have beneficial health effects via numerous mechanisms (Baur and Sinclair, 2006). RES induces apoptosis in human lung adenocarcinoma cells (Alex et al., 2010; Zhang et al., 2011; Zhang et al., 2012b). It also has lung cancer chemopreventive activity by altering the expression of genes involved in the phase I metabolism of polycyclic hydrocarbons (Mollerup et al., 2001). Although the role of the gut and liver is well known in the metabolism of RES (Kuhnle et al., 2000; Miksits et al., 2005; Brill et al., 2006; Iwuchukwu and Nagar, 2008; van de Wetering et al., 2009), the role of lungs has not been evaluated in the metabolism of RES. RES is known to be extensively metabolized into its two major metabolites [i.e., trans-resveratrol-3-sulfate (R3S) and trans-resveratrol-3-glucuronide (R3G)] (Fig. 1) in humans as well as in rodents (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Sharan et al., 2012). A monosulfated metabolite of RES, R3S was recently shown to be biologically active in in vitro studies (Hoshino et al., 2010). Although glucuronides have generally been assumed to be pharmacologically inactive, examples do exist of active glucuronidated metabolites (Osborne et al., 1988; Kroemer and Klotz, 1990). The present work was partially supported by awards from the National Institutes of Health (NIH) National Cancer Institute (NCI) [Grants R03CA133943 and R03CA159389]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or NCI.
RES was purchased from Toronto Research Chemicals. R3S and R3G for calibration were purchased from Toronto Research Chemicals (North York, ON, Canada). The cofactors UDPGA and PAPS (3′-phosphoadenosine-5′-phosphosulfate) were purchased from Sigma-Aldrich (St. Louis, MO). Mouse and human lung fractions were purchased from Xenotech, LLC (Lenexa, KS). Other reagents were purchased from standard sources. All reagents for analytical procedures were of analytical grade.

Animals. Male C57BL/6 mice weighing between 20 and 25 g were supplied by Jackson Laboratory and maintained in the American Association for the Accreditation of Laboratory Animal Care-accredited University Laboratory Animal Resources of Temple University. Animals were fed a normal diet, and water was continuously available. Animals were housed in a standard 12-hour dark/light cycle and were acclimatized for 4 days before the procedure. Animals had free access to food and water during the procedure. All animal studies were approved by the Institutional Animal Care and Use Committee.

Catheterization. Right carotid artery and jugular vein cannulations were performed with the animals under anesthesia with EZ-ANESTHESIA apparatus (Cayman Chemicals, Ann Arbor, MI). The cannulas were tied into place and exteriorized at the back of the neck, and the cannula was flushed with heparin-saline (50 IU/mL, APP Pharmaceuticals, LLC, Schaumburg, IL) to prevent clotting. The cannula was ligated, a small cut was made, and a medical-grade vinyl catheter tubing (0.28-mm inside diameter × 0.64-mm outside diameter, SCI, Lake Havasu City, AZ) with heparin-saline (50 IU/mL, APP Pharmaceuticals, LLC, Schaumburg, IL) was inserted into the right carotid artery. The cannula was tied into place and exteriorized at the back of the neck, and the incision was sutured. The right jugular vein was cannulated in a similar manner. The cannulas were tied in place and exteriorized at the back of the neck, and the incision was sutured. Animals were allowed to recover from the surgery. Animals regained full consciousness and started moving freely 15 minutes after surgery.

Drug Administration and Blood Sampling. RES was solubilized in 20% 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) in saline (Juan et al., 2010b). RES was administered by the IV route at a dose of 15 mg/kg. Carotid artery cannula was used for blood sampling. Heparin-saline (20 μl, 50 IU/mL) was used to flush the cannula after systemic administration or blood sampling. Blood (20 μl) was serially sampled at 2.5, 5, 10, 15, 45, 90, 180, 300, 420, and 600 minutes. Blood samples were centrifuged at 14,000 rpm for 2 minutes, and harvested plasma was collected and stored at −80°C until LC-MS/MS (liquid chromatography - tandem mass spectrometry) analysis. Experiment details of RES IA administration at dose of 15 mg/kg have been previously published (Sharan et al., 2012).

In Vitro Pulmonary Glucuronidation. RES glucuronidation was determined in pooled mouse lung S9 fraction and in pooled human lung microsomes. For mouse lung S9 glucuronidation assay, conditions of protein and time linearity were optimized in preliminary studies. Preliminary experiments showed that the reactions were linear up to 60 minutes and 2.5 mg/ml protein. The incubation mixture consisted of mouse lung S9 fraction (final concentration, 0.5 mg/ml), substrate RES (concentration ranging from 0.01 μM to 5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%), alamethicin (final concentration 10 μM/ml), MgCl2 (final concentration 5 mM), and made up to final incubation volume of 500 μl with Tris-HCl buffer (100 mM, pH 7.4, 37°C). The reaction mixture was preincubated for 3 minutes in a shaking water bath at 37°C. The reaction was started by adding an appropriate volume of the cofactor UDPGA (uridine 5′-diphosphoglucuronic acid, final concentration 5 mM). To 20 μl of reaction mixture, 5 μl of ascorbic acid, and 60 μl of ice-cold methanol containing acetaminophen (APAP) as internal standard (IS) were added at the end of 60 minutes to stop the reaction. All reactions were performed in triplicate. Appropriate negative control experiments were performed under the same conditions but without UDPGA.

For the human lung glucuronidation assay, incubation was performed at 0.1, 0.5, and 2.5 mg/ml (final concentration) human lung microsomes with substrate RES (0.5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%). Preliminary studies showed minimal glucuronidation in human lung microsomes; hence kinetic assays were not conducted.

In Vitro Pulmonary Sulfation. RES sulfation activity was determined in pooled mouse lung S9 fractions and in pooled human lung S9 fractions. Conditions of protein and time linearity were optimized in preliminary studies. Preliminary experiments showed that the reactions were linear up to 60 minutes and 2.5 mg/ml total protein for each protein source. The incubation mixture consisted of mouse lung S9 fractions (final concentration, 1 mg/ml) or human lung S9 fractions (final concentration, 0.5 mg/ml), substrate RES (0.01 μM to 5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%), MgCl2 (5 mM final concentration), and made up to final incubation volume of 500 μl with potassium phosphate buffer (10 mM, pH 6.5, 37°C). The reaction mixture was preincubated for 3 minutes in a shaking water bath at 37°C. The reaction was started by adding an appropriate volume of the cofactor PAPS (final concentration, 1 mM) and incubated in a shaking water bath for 60 minutes at 37°C. To 20 μl of reaction mixture, 5 μl of ascorbic acid and 60 μl of ice-cold methanol containing acetaminophen (APAP; internal standard, or IS) were added at the end of 60 minutes to stop the reaction. All reactions were performed in triplicate. Appropriate negative control experiments were performed under the same conditions but without PAPS.

Protein Binding Assay. Equilibrium dialysis was performed using a 96-well equilibrium dialyzer with MW cutoff of 5K (Harvard Apparatus, Holliston, MA) and placed in dual-plate rotator set to maximum speed (Harvard Apparatus) placed in a 37°C incubator with 10% CO2 atmospheric environment. Frozen mouse plasma was thawed, and its pH was adjusted to 7.4. RES, R3S, and R3G plasma protein binding was determined at a concentration of 20 μM. The protein binding assay was performed with a published protocol (Kochansky et al., 2008).
LC-MS/MS Analysis. RES, R3S, and R3G concentrations in plasma and in the in vitro reaction mixture were measured with an electrospray ionization liquid chromatography-tandem mass spectrometry system (ABSciex API 4000, Framingham, MA) set in negative ion scan mode as described previously (Iwuchukwu et al., 2012). In brief, ascorbic acid (2.5 μl of a 15% solution) was added to 10-μl plasma samples and vortexed for 1 minute. Then 30 μl of methanol containing 78 ng/ml APAP (internal standard) was added and vortexed for 1 minute and centrifuged at 15,000 rpm for 15 minutes at room temperature. For in vitro studies, samples were prepared as described earlier herein. Supernatant (10 μl) was injected into the liquid chromatography tandem mass spectrometry system. The chromatographic separation system consisted of a guard column (Zorbax SB-C18, 5 μm, 4.6 × 12.5 mm; Agilent Technologies, Santa Clara, CA), an analytical column (Zorbax SB-C18, 5 μm, 4.6 × 150 mm; Agilent Technologies) and a gradient mobile phase of A 5 mM ammonium acetate and B methanol. The elution started with 90% A at 0 minutes to 80% at 2 minutes, 65% at 10 minutes, 40% at 12 to 17 minutes, and 90% at 19 minutes. Flow rate of the mobile phase was 1 ml/min, and the flow from the column was split 1:3 into an ABSciex API4000 triple quadrupole mass spectrometer equipped with a Turbo Ionspray source operating at 450°C. The column temperature was maintained at 35°C. The column effluent was monitored at the following precursor-product ion transitions: m/z 227→185 for RES, m/z 150→107 for IS (APAP), 403→113 for R3G, and 307→227 for R3S with a dwell time of 400 ms for each ion transition. The retention time was about 5 minutes for IS (APAP), about 5.9 minutes for R3G, about 9.2 minutes for R3S, and about 14.2 minutes for RES. The lower limit of quantification was 2.4 ng/ml for R3S and 10 ng/ml for R3G and RES.

Noncompartmental Pharmacokinetic Analysis. Pharmacokinetic parameters of RES, R3G, and R3S were analyzed by noncompartmental analysis with Phoenix, WinNonlin (version 6.1, Pharsight Corporation, Palo Alto, CA). The area under the plasma concentration-time curve (AUC) was calculated with the linear trapezoidal method; clearance (CL) was calculated as CL = dose/\( \text{AUC}_{0-\infty} \), volume of distribution at steady state (Vss) was calculated as Vss = CL × MRT\(_{0-\infty}\), the terminal half-life (t\(_1/2\)) was calculated as 0.693/CL, and MRT\(_{0-\infty}\) is the mean residence time from time zero to infinity. The bioavailability (f\(_L\)) of RES after IV and IA administration was calculated by using eq. 1 as follows (Cassidy and Houston, 1980):

\[
f_L = \left( \frac{\text{mean AUC}_{0-\infty, \text{iv.}}}{\text{mean AUC}_{0-\infty, \text{ia.}}} \right) \times 100.
\]

Data Analysis for Enzyme Kinetics. All data were initially transformed, and Eadie-Hofstee (E-H) plots were plotted before nonlinear regression analysis. The Michaelis-Menten model was fit only to data that showed linear E-H plots. The following equation (eq. 2) was used to fit the data showing linear E-H plots, and Michaelis-Menten parameter estimates were determined (Segel, 1993):

\[
v = \frac{\text{Vmax} * [S]}{K_m + [S]},
\]

where \(v\) is the rate of the reaction, Vmax is the maximum velocity estimate, [S] is the substrate concentration, and Km is the Michaelis-Menten constant.

The following equation (eq. 3) was used to fit the data exhibiting partial substrate inhibition profile (Hutzler and Tracy, 2002; Tracy and Hummel, 2004):

\[
v = \frac{\text{Vmax} * [S]}{K_m + [S] + \left( \frac{[S] ^ 2}{K_I} \right)},
\]

where Ki is the partial substrate inhibition constant. Nonlinear regression was performed with GraphPad Prism for Windows (version 4.03; GraphPad Software Inc., San Diego, CA).

Statistics. Student’s unpaired \( t \) test was used, with \( P < 0.05 \) set as the significance level. GraphPad Prism for Windows (version 4.03; GraphPad Software Inc.) was used to perform statistical analysis.

Results

Noncompartmental Pharmacokinetic Analysis of RES. The concentration-time profile of RES and its metabolites after administration of RES via the IV route is shown in Fig. 2. RES (15 mg/kg).

The IA data were previously published (Sharan et al., 2012). Both IV and IA experiments were conducted in parallel under the same laboratory conditions; therefore, we were able to compare the data. RES was metabolized into two major metabolites: R3S and R3G. The results of the noncompartmental pharmacokinetic analysis are summarized in Table 1.

RES exposure (294.98 ± 137.87 minutes*μM) and half-life (101.30 ± 43.41 minutes) after IV administration were significantly lower than its exposure (591.08 ± 167.29 minutes*μM) and half-life (190.58 ± 69.65 minutes) after IA administration (AUC: \( P = 0.01 \), \( t_{1/2} \): \( P = 0.04 \)). The bioavailability (\( f_L \)) of RES after IV administration was 49.9%. The clearance and volume of distribution at steady state of RES after IV administration were not statistically significantly different compared with those after IA administration (CL: \( P = 0.05 \), Vss: \( P = 0.85 \)). Interestingly, it was observed that the exposure of R3G (2268.35 ± 517.00 minutes*μM) after IV administration of RES increased significantly compared with R3G exposure (921.23 ± 457.07 minutes*μM) after RES IA administration (\( P = 0.004 \)). No significant change was observed in the exposure of R3S after RES administration by both routes (\( P = 0.67 \)).

The plasma protein binding of RES, R3G, and R3S in mouse plasma was found to be 91.95 ± 0.99, 66.75 ± 1.56, and 87.24 ± 4.89% (mean ± SD, \( n = 3 \)) respectively.

In Vitro Pulmonary Metabolism. The glucuronidation of RES was studied in mouse and human lung fractions. Figure 3A shows the formation rate of R3G in mouse lung fraction with its Eadie-Hofste
The E-H plot shown as inset. The R3G profile exhibited partial substrate inhibition. This was determined by fitting the data to the partial substrate inhibition equation (eq. 3); the inset represents Eadie-Hofstee plots.

Fig. 3. In vitro kinetics of (A) R3G formation in mouse lung S9 fraction, (B) R3S formation in mouse lung S9 fraction, and (C) R3S formation in human lung S9 fraction. Data are reported as mean ± S.D. (n = 3). The solid line represents curve fitting with the partial substrate inhibition equation (eq. 3); the inset represents Eadie-Hofstee plots.

Discussion

RES is known to be extensively metabolized into its conjugates, mainly R3G and R3S (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Iwuchukwu et al., 2012). Lungs are the third in a series of three potential biotransformation sites (along with the gut and liver) that orally ingested RES must cross before entering the general circulation. First-pass metabolism by gut, liver, and lungs in series can synergistically increase total body clearance of RES. Although the role of gut and liver in the metabolism of RES is known (Miksits et al., 2005; Brill et al., 2006; Iwuchukwu and Nagar, 2008), the contribution of lungs to RES metabolism has not been evaluated. In the present study, the contribution of lungs in the metabolism of RES was evaluated using multiple sites of administration and a single site of sampling design (Cassidy and Houston, 1980) in a mouse model. The in vivo study clearly demonstrated the contribution of lungs in the glucuronidation of RES to R3G in mice. In vivo results were corroborated by in vitro studies in mouse lung fractions.

Because species-dependent differences in metabolism are known, in vitro studies were also conducted in human lung fractions to determine whether reliable extrapolation of data can be made between mice and humans. Interestingly, no significant glucuronidation of RES was observed in human lung fractions, implying that the contribution of pulmonary glucuronidation in the metabolism of RES might be quantitatively less important in humans. The species difference in RES glucuronidation at its 3-OH position can be explained by differential expression of uridine 5'-diphosphoglucuronosyltransferase (UGT) isoforms in mouse and human lungs. RES has been reported to be glucuronidated at its 3-OH position via UGT1A1, UGT1A7, and UGT1A9, with minor contribution from UGT1A6, UGT1A8, UGT1A10, and UGT2B7 (Brill et al., 2006). Ugt1a6 has been shown to be expressed well in mouse lung (Buckley and Klaassen, 2007) and might be responsible for RES glucuronidation in mouse lungs. There are conflicting reports about the presence of UGT enzymes in human lung. UGT1A1 and UGT1A10 have been reported in lung cancer samples (Oguri et al., 2004). Several UGT2B isozymes are reportedly present in human lungs (Turgeon et al., 2001). UGT expression and activity have been reported in the upper respiratory tract but not in lungs in humans (Zheng et al., 2002), which becomes important for inhaled compounds. Other studies have shown low or no UGT expression in normal human lung tissue (Zheng et al., 2002; Somers et al., 2007; Nakamura et al., 2008). In the present study, the absence of R3G formation in human lung fraction is consistent with low or absent expression of UGT isoforms in normal human lung tissue (Nakamura et al., 2008) responsible for RES glucuronidation (Brill et al., 2006).

Sulfation experiments showed that RES is sulfated by both mouse and human lungs. RES sulfation at its 3-OH position has been reported via sulfotransferase (SULT) 1A1, 1A2, 1A3, and 1E1 isoforms (Miksits et al., 2005). Mouse lungs express sult1a1, with very low expression of sult1e1 (Alnouti and Klaassen, 2006). SULT1A1, SULT1A3, SULT1E1, SULT2A1, and SULT1B1 are expressed in human lungs, and SULT1A1, SULT1A3, and microsomes, no R3G was observed above LOQ (limit of quantitation, 10 ng/ml for R3G) at the end of 60 minutes’ incubation. Therefore, no further RES glucuronidation kinetic studies were performed with human lung microsomes.

Fig. 3, B and C show the formation kinetics of R3S in mouse and human lung fractions with E-H plots as insets respectively. R3S formation in both mouse and human lung fractions showed partial substrate inhibition (Hutzler and Tracy, 2002).
SULT1E1 account for around 80% of all SULTs expressed in human lungs (Riches et al., 2009). Therefore, sul1ta1 and sul1te1 in mouse lungs and SULT1A1, SULT1A3, and SULT1E1 in human lungs might be responsible for R3S formation. Steroid sulfatase activity has been reported in both human (Milestone et al., 1983) and mouse lung tissue (Milestone et al., 1984), with the highest activity in microsomal fractions of human lung tissue homogenates (Milestone et al., 1983). Steroid sulfatase can desulfate R3S to give RES locally in the lung cells. This futile cycling of RES/R3S by the combined activity of sulfatase and sulfotransferase enzyme can lead to an increase in the retention of the RES/R3S within the lung. This can be important since RES and R3S both have been shown to have pharmacological activity in vitro (Hoshino et al., 2010).

Transporters, in conjunction with metabolizing enzymes, play an important role in the disposition of drugs and metabolites. R3G and R3S disposition is known to be influenced by transporters. R3G has been shown to be a high affinity substrate for human multidrug resistance protein transporter (MRP) 2 (ABCC2), MRP3 (ABCC3), and human breast cancer resistance protein (BCRP; ABCG2) transporters (Maier-Salamon et al., 2008; van de Wetering et al., 2009; Juan et al., 2010a). Although the role of MRP1 (ABCC1) specifically in R3G transport has not been evaluated, there are reports of MRP1-mediated transport of glucuronides such as 17β-estradiol-glucuronide (Jedlitschky et al., 1996), etoposide glucuronides, SN-38 glucuronide (Deeley and Cole, 2006), and β-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (Leslie et al., 2001). BCRP and MRP2 are involved in the transport of RES (van de Wetering et al., 2009; Juan et al., 2010a). MRP4 (ABCC4) and MRP1 (ABCC1) have not been studied for R3S transport, but both MRP4 and MRP1 are reportedly involved in the transport of sulfo-conjugates such as dehydroepiandrosterone sulfate (Zelcer et al., 2003) and estrone 3-sulfate (Qian et al., 2001). Mouse lungs have been shown to express Mrp1, Mrp3, and Mrp4 transporters (Maher et al., 2005). It is interesting that mouse lungs did not express Mrp2 and Bcrp transporter (Scheffer et al., 2002; Maher et al., 2005).

Cellular distribution and localization of transporters in mouse lungs are unknown, although cellular distribution and localization of MRP1, MRP2, and BCRP in human lungs are reported. MRP1 is expressed on the basolateral membrane, whereas MRP2 and BCRP are expressed toward the apical membrane in human lungs (Bosquillon, 2010). Although cellular localization of MRP3 and MRP4 transporters is unknown in lungs, they are expressed on the basolateral side in hepatocytes (Zamek-Gliszczynski et al., 2006).

Based on present results and previous reports (Maher et al., 2005; Bosquillon, 2010), a simplified scheme for the disposition of RES, R3S, and R3G in mouse lung cells is proposed (Fig. 4A). RES, administered by the IV route, can diffuse into mouse lung cells and can either get metabolized by sulft enzymes present in the cytosol or get conjugated to glucuronides or sulfates. These conjugates can then be transported out of the cell by transporters such as Mrp3 and possibly Mrp1. RES that is not conjugated or conjugated to Mrp3 can then be transported further into the blood by Mrp3 transporter (Maher et al., 2005). It is interesting that mouse lungs did not express Mrp2 and Bcrp transporter (Scheffer et al., 2002; Maher et al., 2005).

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Conjugation Product</th>
<th>Protein Source</th>
<th>Vmax (pmol/min/mg)</th>
<th>Km (μM)</th>
<th>Ki (μM)</th>
<th>Goodness of Fit (r²)</th>
<th>Type of Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>RES</td>
<td>R3G</td>
<td>Mouse lung S9</td>
<td>324.40 ± 13.05</td>
<td>7.34 ± 1.60</td>
<td>6632 ± 1198</td>
<td>0.93</td>
<td>Partial substrate inhibition</td>
</tr>
<tr>
<td>RES</td>
<td>R3S</td>
<td>Mouse lung S9</td>
<td>152.63 ± 1.72</td>
<td>22.41 ± 0.78</td>
<td>2321 ± 717.6</td>
<td>0.96</td>
<td>Partial substrate inhibition</td>
</tr>
<tr>
<td>RES</td>
<td>R3S</td>
<td>Human lung S9</td>
<td>266 ± 0.48</td>
<td>23.28 ± 0.79</td>
<td>2321 ± 717.6</td>
<td>0.65</td>
<td>Partial substrate inhibition</td>
</tr>
</tbody>
</table>

Ki, partial substrate inhibition constant; Km, the Michaelis-Menten constant; R3G, trans-resveratrol-3-O-glucuronide; R3S, trans-resveratrol-3-sulfate; RES, trans-3,5,4'-trihydroxystilbene (trans-resveratrol).
Fig. 4. Proposed schematic representation of RES metabolism in (A) mouse lung cells and (B) human lung cells. Solid arrows represent pathways based on results in this manuscript and published literature reports for metabolism and/or transport of RES, R3S, and R3G. Transporters followed by “?” indicates that the role of these transporters has not been established for transport of R3S and R3G but is hypothesized based on literature detailed in the Discussion.
Acknowledgments

The authors thank Temple University School of Pharmacy for support and Priyanka Kulkarni for technical assistance.

Authorship Contributions

Participated in research design: Shanar, Nagar.
Conducted experiments: Shanar.
Performed data analysis: Shanar, Nagar.
Wrote or contributed to the writing of the manuscript: Shanar, Nagar.

References


Lancet 1:828.


